Clinical Trial: A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06941350) titled 'A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD' on April 16.

Brief Summary: Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.

Study Start Date: April 28

Study Type: INTERVENTIONAL

Condition: Acute Graft-versus-Host Disease

Intervention: BIOLOGICAL: NCR102 injection

Twice a week for 4 weeks, and the treatment continues for another 4 weeks in subjects with partial remission by day 28.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Nuwacell Biotechnologies Co., Ltd.

Disclaimer: Curated by HT Syndication....